<?xml version="1.0" encoding="UTF-8"?>
<p id="Par48">Surprisingly, systemic anti-IgE treatment was also shown to markedly reduce infection-induced severe asthma exacerbations. A year-round treatment with omalizumab has been shown to abolish the seasonal peaks in asthma exacerbations, most of which are associated with RV infection [
 <xref ref-type="bibr" rid="CR84">84</xref>]. Parallel to the IgE neutralization by the drug, clinical benefit was associated with enhanced IFN-Î³ responses, suggesting that omalizumab may improve the anti-viral responses [
 <xref ref-type="bibr" rid="CR88">88</xref>].
</p>
